TP53 and cholangiocarcinoma: All these data are partially consistent with our results, and our research could reinforce previous insights on the genomic landscape of CCA, mainly concerning the negative prognostic role of TP53. On the other hand, our analysis focused on the IDH1 mutations, thus providing, for the first time, a large sample of IDH1m patients.